Chicago – November 03, 2025
A pharmaceutical company has issued a voluntary recall for more than a half-million bottles of blood pressure medication after tests showed the capsules had high levels of potentially cancer-causing chemicals.
An enforcement report from the Food and Drug Administration said New Jersey-based Teva Pharmaceuticals USA Inc. recalled 580,844 bottles of Prazosin Hydrochloride capsules that were distributed nationwide.
According to the report, the recall was initiated because tests for the capsules, which came in doses of 1, 2 and 5 mg, showed they had “above acceptable intake limits” for N-nitroso Prazosin impurity C, a cancer-linked chemical compound.
The recall was initiated Oct. 7, the report said. Oct. 24, the recall was classified as a “Class II,” which means the product “may cause temporary or medically reversible adverse health consequences,” or where the probability of serious adverse health consequences is remote.
According to the Health Hazard Assessment by Teva USA, the overall harm in the patient population is considered to be medium, the California Board of Pharmacy said in a memo.
In total, 55 lots of the pills were recalled. A full list of impacted lot codes can be found here.
In a statement sent to NBC Chicago, Teva confirmed its voluntary, nationwide recall of Prazosin Hydrocholoride Capsules USP in 1mg, 2mg and 5 mg.
Teva went on to say that it had not receive any “relevant complaints” related to the product.
“Prazosin is indicated for the treatment of hypertension, to lower blood pressure, and there are many alternative treatments available to patients,” the statement said. “Teva prioritizes patient safety and product quality at every stage of a medicine’s lifecycle.”
